BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/30/2024 9:47:23 AM | Browse: 226 | Download: 1010
 |
Received |
|
2024-06-29 01:48 |
|
Peer-Review Started |
|
2024-06-29 01:48 |
|
First Decision by Editorial Office Director |
|
2024-09-29 13:01 |
|
Return for Revision |
|
2024-09-29 13:01 |
|
Revised |
|
2024-10-11 04:17 |
|
Publication Fee Transferred |
|
2024-12-02 13:00 |
|
Second Decision by Editor |
|
2024-10-24 02:54 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-02 10:27 |
|
Articles in Press |
|
2024-12-02 10:27 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-12-09 02:13 |
|
Publish the Manuscript Online |
|
2024-12-30 09:47 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Prospective Study |
| Article Title |
Efficacy of sodium−glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Di-Fei Lu, Rui Zheng, Ang Li and Jun-Qing Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jun-Qing Zhang, MD, PhD, Department of Endocrinology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. junqing.zhang@pkufh.com |
| Key Words |
Type 2 diabetes; Chronic kidney disease; Body weight; Sodium-glucose cotransporter-2 inhibitors; Glucagon-like peptide-1 receptor agonists |
| Core Tip |
In this study, a cohort of 5482 patients with type 2 diabetes were enrolled and followed up for at least 6 months. After propensity score matching, patients who received GLP-1RA or SGLT2i were compared with those who did not receive either treatment. Patients with increased BMIs were predisposed to treatment with GLP-1RAs, and those with higher UACRs were more likely to be treated with SGLT2is. Patients on SGLT2i or GLP-1RAs showed significant weight loss, a decreasing trend in UACR and comparable glucose-lowering effects compared with patients who received glucose-lowering drugs other than SGLT2i or GLP-1RA in real-world settings. |
| Publish Date |
2024-12-30 09:47 |
| Citation |
Lu DF, Zheng R, Li A, Zhang JQ. Efficacy of sodium−glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort. World J Diabetes 2025; 16(2): 98552 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i2/98552.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i2.98552 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
